Hikma Pharmaceuticals (LON:HIK) Receives “Buy” Rating from Deutsche Bank Aktiengesellschaft

Deutsche Bank Aktiengesellschaft reiterated their buy rating on shares of Hikma Pharmaceuticals (LON:HIK) in a report published on Tuesday morning, Marketbeat.com reports. They currently have a GBX 2,750 ($34.94) price objective on the stock.

Other research analysts have also issued research reports about the company. Berenberg Bank reiterated a hold rating and set a GBX 2,000 ($25.41) target price on shares of Hikma Pharmaceuticals in a research report on Thursday, April 25th. Barclays reaffirmed an equal weight rating and set a GBX 2,000 ($25.41) price objective on shares of Hikma Pharmaceuticals in a report on Tuesday, May 7th. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of Moderate Buy and a consensus price target of GBX 2,225 ($28.27).

Hikma Pharmaceuticals Stock Performance

Shares of HIK stock opened at GBX 1,999 ($25.40) on Tuesday. Hikma Pharmaceuticals has a 52-week low of GBX 1,711 ($21.74) and a 52-week high of GBX 2,222 ($28.23). The company has a quick ratio of 1.27, a current ratio of 1.57 and a debt-to-equity ratio of 53.92. The stock has a market cap of £4.44 billion, a PE ratio of 2,983.58, a price-to-earnings-growth ratio of 2.38 and a beta of 0.44. The business has a 50-day simple moving average of GBX 1,922.71 and a 200-day simple moving average of GBX 1,896.66.

Insider Buying and Selling

In related news, insider Riad Mishlawi acquired 736 shares of Hikma Pharmaceuticals stock in a transaction dated Tuesday, May 7th. The stock was acquired at an average price of GBX 1,979 ($25.15) per share, for a total transaction of £14,565.44 ($18,507.55). 30.62% of the stock is owned by insiders.

Hikma Pharmaceuticals Company Profile

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals.